The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors

British Journal of Pharmacology

Volumn 129, Issue 7, 2000, Pages 1465-1473

  El Yacoubi, Malika ^a   Ledent, Catherine ^b   Ménard, Jean François ^c   Parmentier, Marc ^b   Costentin, Jean ^a   Vaugeois, Jean Marie ^a  

^a IFRMP 23   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c HÔPITAL CHARLES NICOLLE   (France)

Author keywords

A(2A) receptor; Adenosine; Caffeine; DPCPX; Habituation; Knockout mice; Locomotor activity; SCH 58261

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; CYCLOPENTYLADENOSINE; UNCLASSIFIED DRUG;

ACTIMETRY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HABITUATION; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL;

EID: 0034023862     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703170     Document Type: Article

References (62)

1. Abercrombie, E.D., Keefe, K.A., Di Frischia, D.S. & Zigmond M.J. (1989). Differential effect of stress on in vivo dopamine release in striatum, nucleus accubens, and medial frontal cortex. J. Neurochem., 52, 1655-1658.
2. Al'Absi, M., Lovallo, W.R., McKey, B., Sung, B.H., Whitsett, T.L. & Wilson, M.F. (1998). Hypothalamic-pituitary-adrenocortical responses to psychological stress and caffeine in men at high and low risk for hypertension. Psychosom. Med., 60, 521-527.
3. Al-Khatib, I.M.H., Dökmeci, I. & Fujiwara, M. (1995). Differential role of nucleus accumbens and caudate-putamen in mediating the effect of nomifensine and methamphetamine on ambulation and rearing of rats in the open-field test. Jpn. J. Pharmacol., 67, 69-77.
4. Antelman, S.M., Eichler, A.J., Black, C.A. & Kocan, D. (1980). Interchangeability of stress and amphetamine in sensitization. Science, 207, 329-331.
5. 2A adenosine receptors on sleep-waking patterns in rats. Drug Dev. Res., 37, 65-72.
6. 1 adenosine receptors. Brain Res., 599, 6-12.
7. Boissier, J.R. & Simon, P. (1965). Action de la caféine sur la motilité spontanée de la souris. Arch. Int. Pharmacodyn., 158, 212-221.
8. Boulenger, J.P., Uhde, T.W., Wolff, E.A. 3D & Post, R.M. (1984). Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch. Gen. Psychiatry, 41, 1067-1071.
9. Britton, D.R. & Indyk, E. (1990). Central effects of corticotropin releasing factor (CRF): evidence for similar interactions with environmental novelty and with caffeine. Psychopharmacology, 101, 366-370.
10. 2 adenosine receptor subtypes in locomotor activity and place conditioning in rats. Behav. Pharmacol., 7, 373-383.
11. Charney, D.S., Heninger, G.R. & Jatlow, P.I. (1985). Increased anxiogenic effects of caffeine in panic disorders. Arch. Gen. Psychiatry, 42, 233-243.
12. Dunwiddie, T.V. & Worth, T. (1982). Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther., 220, 70-76.
13. Durcan, M.J. & Morgan, P.F. (1989). NECA-induced hypomobility in mice: evidence for a predominantly central site of action. Pharmacol. Biochem. Behav., 32, 487-490.
14. 1 receptor antagonists and agonists in mice. Drug Dev. Res., 43, 54.
15. Ferré, S. (1997). Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology, 133, 107-120.
16. Ferré, S., Fredholm, B.B., Morelli, M., Popoli, P. & Fuxe, K. (1997). Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci., 20, 482-487.
17. Finn, I.B., Iuvone, P.M. & Holtzman, S.G. (1990). Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate. Neuropharmacology, 29, 625-631.
18. Florio, C.A., Rosati, A., Traversa, U. & Vertua, R. (1997). Inhibitory and excitatory effects of adenosine antagonists on spontaneous locomotor activity in mice. Life Sci., 60, 1477-1486.
19. Fredholm, B.B. (1980). Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci., 1, 129-132.
20. Fredholm, B.B. (1995). Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol., 76, 93-101.
21. Fredholm, B.B., Bättig, K., Holmen, J., Nehlig, A. & Zvartau, E.E. (1999). Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev., 51, 83-133.
22. 1-selective antagonist, DPCPX. Psychopharmacology, 103, 541-544.
23. Griffiths, R.R. & Woodson, P.P. (1988). Reinforcing effects of caffeine in humans. J. Pharmacol. Exp. Ther., 246, 21-29.
24. Heffner, T.G., Wiley, J.N., Williams, A.E., Bruns, R.F., Coughenour, L.L. & Downs, D.A. (1989). Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology, 98, 31-37.
25. Henry, J.P. & Stephens, P.M. (1980). Caffeine as an intensifier of stress-induced hormonal and pathophysiologic changes in mice. Pharmacol. Biochem. Behav., 13, 719-727.
26. Holtzman, S.G. (1991). CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats. Life Sci., 49, 1563-1570.
27. 2-adenosine antagonist in vitro and in vivo. FEBS Lett., 323, 141-144.
28. Jacobson, K.A. & Van Rhee, M. (1997). Development of selective purinoceptor agonists and antagonists. In: Purinergic approaches in experimental therapeutics. Jacobson, K.A. & Jarvis, M.F. (eds). New York: Wiley-Liss. pp. 101-128.
29. Jain, N., Kemp, N., Adeyemo, O., Buchanan, P. & Stone, T.W. (1995). Anxiolytic activity of adenosine receptor activation in mice. Br. J. Pharmacol., 116, 2127-2133.
30. Jarvis, M.F. (1997). Psychomotor aspects of adenosine receptor activation. In: Purinergic approaches in experimental therapeutics. Jacobson, K.A. & Jarvis, M.F. (eds). New York: Wiley-Liss. pp. 405-421.
31. Johansson, B., Georgiev, V., Kuosmanen, T. & Fredholm, B.B. (1996). Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline-and pentylenetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur. J. Neurosci., 8, 2447-2458.
32. 1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Res., 762, 153-164.
33. 1 adenosine receptor occupancy. Neuropsychopharmacology, 6, 145-153.
34. Kaplan, G.B., Greenblatt, D.J., Leduc, B.W., Thompson, M.L. & Shader, R.I. (1989). Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J. Pharmacol. Exp. Ther., 248, 1078-1083.
35. Katims, J.J., Annau, Z. & Snyder, S.H. (1983). Interactions in the behavioral effects of methylxanthines and adenosine derivatives. J. Pharmacol. Exp. Ther., 227, 167-173.
36. Kendler, K.S. & Prescott, C.A. (1999). Caffeine intake, tolerance, and withdrawal in women: a population-based twin study. Am. J. Psychiatry, 156, 223-228.
37. 2A receptor. Nature, 388, 674-678.
38. Libert, F., Parmentier, M., Lefort, A., Dinsart, C., Van Sande, J., Maenhaut, C., Simons, M.J., Dumont, J.E. & Vassart, G. (1989). Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science, 244, 569-572.
39. 1 adenosine receptor. EMBO J., 10, 1677-1682.
40. Logan, L., Seale, T.W. & Carney, J.M. (1986). Inherent differences in sensitivity to methylxanthines among inbred mice. Pharmacol. Biochem. Behav., 24, 1281-1286.
41. 2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Commun., 173, 1169-1178.
42. 1 receptors, using in vivo and in vitro techniques. J. Pharmacol. Exp. Ther., 285, 1023-1030.
43. Misslin, R., Herzog, F., Koch, B. & Ropartz, P. (1982). Effects of isolation, handling and novelty on the pituitary-adrenal response in the mouse. Psychoneuroendocrinology, 7, 217-221.
44. Nikodijevic, O. & Jacobson, K.A. (1993). Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol. Biochem. Behav., 44, 199-216.
45. 2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther., 259, 286-294.
46. 2A adenosine receptor antagonist. Drug Dev. Res., 42, 63-70.
47. 2A receptors. Trends Pharmacol. Sci., 17, 364-372.
48. 2A receptor in sleep promotion. Eur. J. Pharmacol., 351, 155-162.
49. 6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur. J. Pharmacol., 300, 163-171.
50. Seale, T.W., Abla, K.A., Shamim, M.T., Carney, J.M. & Daly, J.W. (1988). 3,7-dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs. Life Sci., 43, 1671-1684.
51. Snyder, S.H. (1997). Knockouts anxious for new therapy. Nature, 388, 624.
52. Snyder, S.H., Katims, J.J., Annau, Z., Bruns, R.F. & Daly, J.W. (1981). Adenosine receptors and behavioral actions of methylxanthines. Proc. Natl. Acad. Sci. U.S.A., 78, 3260-3264.
53. Spindel, E., Griffith, L. & Wurtman, R.J. (1983). Neuroendocrine effects of caffeine. II. Effects on thyrotropin and corticosterone secretion. J. Pharmacol. Exp. Ther., 225, 346-350.
54. Stiles, G.L. (1997). Adenosine receptor subtypes: new insights from cloning and functional studies. In: Purinergic approaches in experimental therapeutics. Jacobson, K.A. & Jarvis, M.F. (eds). New York: Wiley-Liss. pp. 29-37.
55. Svenningsson, P., Nomikos, G.G. & Fredholm, B.B. (1995). Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J. Neurosci., 15, 7612-7624.
56. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience, 79, 753-764.
57. Thithapandha, A., Maling, H.M. & Gillette, J.R. (1972). Effects of caffeine and theophylline on activity of rats in relation to brain xanthine concentrations. Proc. Soc. Exp. Biol. Med., 139, 582-586.
58. Uhde, T.W., Boulenger, J.-P., Jimerson, D.C. & Post, R.M. (1984). Caffeine: relationship to human anxiety, plasma MHPG and cortisol. Psychopharmacol. Bull., 20, 426-430.
59. Van Calker, D., Muller, M. & Hamprecht, B. (1979). Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem., 33, 999-1005.
60. Waldeck, B. (1975). Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta. Pharmacol. Toxicol., 36, (Suppl. 4), 1-23.
61. 1 receptor mediation. Neuropharmacology, 28, 21-25.
62. Yanik, G., Glaum, S. & Radulovacki, M. (1987). The dose-response effects of caffeine on sleep in rat. Brain Res., 403, 177-180.